IP Library Granted Patent US 11,988,673
Granted Patent B2
US 11,988,673 · App. 17/389,757 · Granted May 21, 2024

Multiplexed immunohistochemistry using recombinant antibodies with epitope tags

Inventors: Michael Farrell (Tucson, AZ); Antony Hubbard (Tucson, AZ); Eric May (Oro Valley, AZ); Lei Tang (Oro Valley, AZ); Tsu-Shuen Tsao (Tucson, AZ); Wenjun Zhang (Tucson, AZ)
Assignee: Ventana Medical Systems, Inc.
G01N33/6878C07K16/18C07K16/2809C07K16/2815C07K16/2827C07K16/2887C07K16/2896C07K16/32C07K2319/40C07K2319/42G01N2570/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,988,673
App. No.
17/389,757
Granted
May 21, 2024
Kind
B2
Abstract

The present disclosure is directed to epitope-tagged antibodies, as well as methods of employing the epitope-tagged antibodies for detecting one or more targets in a biological sample, e.g. a tissue sample.

Claims (36)

1. A multiplex immunohistochemical method for detecting a plurality of targets in a sample, wherein the method comprises the steps of:

(a) simultaneously contacting the sample with:

(a1) a first epitope-tagged primary antibody, wherein the first epitope-tagged primary antibody comprises:

(i) a first antibody specific to a first target, and

(ii) at least a first epitope tag construct, wherein the first epitope tag construct comprises alternating spacers and a first epitope tag; and

(a2) a second epitope-tagged primary antibody, wherein the second epitope-tagged primary antibody comprises:

(i) a second antibody specific to a second target that is different from the first target and wherein the first antibody and the second antibody are same-species antibodies; and

(ii) at least a second epitope tag construct, wherein the second epitope tag construct comprises alternating spacers and a second epitope tag, and wherein the second epitope tag is different from the first epitope tag; and

(b) contacting the sample with a first set of detection reagents for detecting binding of the first epitope-tagged primary antibody to the sample, wherein the first set of detection reagents comprises a first anti-tag antibody, wherein the first anti-tag antibody is specific for the first epitope tag; and

(c) contacting the sample with a second set of detection reagents for detecting binding of the second epitope-tagged primary antibody to the sample, wherein the set of detection reagents comprises a second anti-tag antibody, wherein the second anti-tag antibody is specific for the second epitope tag.

2. The method of claim 1 , wherein the sample is simultaneously contacted with the first and second anti-tag antibodies.

3. The method of claim 1 , wherein the first epitope-tagged primary antibody and the second epitope-tagged prim ay antibody are applied as a first mixture; and wherein the first and second anti-tag antibodies are applied as a second mixture.

4. The method of claim 1 , wherein the epitope tag construct has the structure (-[Spacer]-[Epitope Tag]-), wherein the structure is repeated from 1 to 12 times.

5. The method of claim 1 or 4 , wherein the method further comprises the steps of:

(d) contacting the sample with a third primary antibody specific to a third target; and

(e) contacting the sample with a third set of detection reagents for detecting binding of the third primary antibody to the sample, wherein the third set of detection reagents comprises an antibody specific for the third antibody.

6. The method of claim 5 , wherein the third primary antibody is a third epitope-tagged antibody, wherein the third epitope-tagged primary antibody comprises:

(i) a third antibody specific to the third target, and

(ii) a third epitope tag construct, wherein the third epitope tag construct comprises at least 2 repeats of a third epitope tag, wherein the repeats of the third epitope tag are separated by a spacer; and

wherein the antibody specific for the third antibody is a third anti-tag antibody, wherein the third anti-tag antibody is specific for the third epitope tag.

7. The method of claim 6 , wherein the sample is simultaneously contacted with the first epitope-tagged primary antibody, the second epitope-tagged primary antibody, and the third epitope-tagged primary antibody.

8. The method of claim 7 , wherein the sample is simultaneously contacted with the anti-tag antibodies.

9. The method of claim 8 , wherein the first epitope-tagged primary antibody, the second epitope-tagged primary antibody, and the third primary antibody are applied as a first mixture; and wherein the anti-tag antibodies are applied as a second mixture.

10. The method of claim 5 , wherein the third primary antibody does not comprise an epitope tag and has a species that is different from the first antibody and the second antibody, and wherein the antibody specific for the third antibody is an anti-species secondary antibody.

11. The method of claim 1 , wherein the first epitope tag construct is expressed at a C-terminus of a heavy chain of the first antibody; and the second epitope tag construct is expressed at a C-terminus of a heavy chain of the second antibody.

12. The method of claim 11 , wherein:

the first epitope-tagged antibody further comprises the first epitope tag construct expressed at a C-terminus of a light chain of the first antibody; and

the second antibody further comprises the second epitope tag construct expressed at a C-terminus of the light chain.

13. The method of claim 11 , wherein:

the first epitope tag construct comprises at least 2 epitope tags; and

the second epitope tag construct comprises at least 2 epitope tags.

14. The method of claim 13 , wherein:

the first epitope-tagged antibody has a configuration selected from the group consisting of H2K0, H3K0, H4K0, H5K0, H2K2, H3K3, and H4K4; and

the second epitope-tagged antibody has a configuration selected from the group consisting of H2K0, H3K0, H4K0, H5K0, H2K2, H3K3, and H4K4.

15. The method of claim 1 , wherein the first epitope tag construct is expressed at a C-terminus of a light chain of the first antibody; and the second epitope tag construct is expressed at a C-terminus of a light chain of the second antibody.

16. The method of claim 15 , wherein the first epitope-tagged antibody has a configuration H0K4; and the second epitope-tagged antibody has a configuration H0K4.

Continuity (6)
Division 16123750 · Sep 6, 2018
Continuation PCTUS2017021157 · Mar 7, 2017
Provisional Application 62461651 · Feb 21, 2017
Provisional Application 62418667 · Nov 7, 2016
Provisional Application 62305440 · Mar 8, 2016
Related Publication 20220057408A1 · Feb 24, 2022